Nicotine Addiction - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nicotine Addiction - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Nicotine Addiction - Pipeline Review, H2 2016', provides an overview of the Nicotine Addiction pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Nicotine Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction
- The report reviews pipeline therapeutics for Nicotine Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Nicotine Addiction therapeutics and enlists all their major and minor projects
- The report assesses Nicotine Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Nicotine Addiction

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nicotine Addiction Overview 7
Therapeutics Development 8
Pipeline Products for Nicotine Addiction - Overview 8
Pipeline Products for Nicotine Addiction - Comparative Analysis 9
Nicotine Addiction - Therapeutics under Development by Companies 10
Nicotine Addiction - Therapeutics under Investigation by Universities/Institutes 11
Nicotine Addiction - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Nicotine Addiction - Products under Development by Companies 14
Nicotine Addiction - Products under Investigation by Universities/Institutes 15
Nicotine Addiction - Companies Involved in Therapeutics Development 16
Addex Therapeutics Ltd 16
Astraea Therapeutics, LLC 17
Cerecor Inc. 18
Chronos Therapeutics Limited 19
Embera NeuroTherapeutics, Inc. 20
Hager Biosciences, LLC 21
Heptares Therapeutics Limited 22
Omeros Corporation 23
Nicotine Addiction - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 31
Drug Profiles 33
(metyrapone + oxazepam) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ADX-71441 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
AT-1001 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CERC-501 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
EORA-101 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
OMS-405 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
OMS-527 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecule for Nicotine Addiction - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecule for Psychiatric Disorders - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
URB-694 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Vaccine for Nicotine Addiction - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Vaccine for Nicotine Addiction - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Vaccine for Nicotine Addiction - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Vaccine for Nicotine Addiction - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Nicotine Addiction - Dormant Projects 58
Nicotine Addiction - Discontinued Products 59
Nicotine Addiction - Product Development Milestones 60
Featured News & Press Releases 60
Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501 60
Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction 60
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 61
Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine 61
May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables

Number of Products under Development for Nicotine Addiction, H2 2016 8
Number of Products under Development for Nicotine Addiction - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H2 2016 16
Nicotine Addiction - Pipeline by Astraea Therapeutics, LLC, H2 2016 17
Nicotine Addiction - Pipeline by Cerecor Inc., H2 2016 18
Nicotine Addiction - Pipeline by Chronos Therapeutics Limited, H2 2016 19
Nicotine Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H2 2016 20
Nicotine Addiction - Pipeline by Hager Biosciences, LLC, H2 2016 21
Nicotine Addiction - Pipeline by Heptares Therapeutics Limited, H2 2016 22
Nicotine Addiction - Pipeline by Omeros Corporation, H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Assessment by Combination Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Nicotine Addiction - Dormant Projects, H2 2016 58
Nicotine Addiction - Discontinued Products, H2 2016 59